A recent study has tested a novel radiation therapy called boron neutron capture therapy (BNCT) on canine HSA cells for the first time.
BNCT is a two-step process. First, a boron compound called BPA is injected. Cancer cells take up this compound through a protein on their surface called LAT1, which is highly active on many tumor cells. Normal cells take up much less.
Second, the tumor is exposed to thermal neutrons. The boron atoms capture the neutrons and undergo a tiny nuclear explosion, releasing particles that travel less than the width of a single cell. This means cancer cells that took up the boron are killed, while nearby healthy tissue is largely spared.
BNCT has shown promise against human angiosarcoma, but it had never been tested in canine HSA until now.
Researchers tested three different canine HSA cell lines in the lab. They found that all three took up BPA through LAT1. When they blocked LAT1 with an inhibitor, BPA uptake dropped significantly, confirming the transporter’s role.
When the cells were exposed to neutron irradiation, BNCT with BPA killed significantly more cells than neutrons alone or X-rays. The cells that took up the most boron saw the strongest effect.
This is the first proof that canine HSA cells can take up enough boron to make BNCT a viable strategy. The boron concentration used in the lab (28 ppm) falls within the range achievable in real patients, where tumor levels are estimated at 30–42 ppm.
The study also calculated compound biological effectiveness (CBE) values for each cell line, a conversion factor that helps determine the effective radiation dose. These values ranged from 1.25 to 2.60, indicating that BNCT responsiveness may vary between tumors.
The authors caution that this was an in vitro study only. They did not directly measure LAT1 protein levels, so the link between expression and uptake is inferred but not proven. BPA uptake was only tracked for two hours, leaving longer-term retention unknown.
Most importantly, no comparison was made with normal canine cells, so tumor selectivity and safety margins are not yet established. The complex tumor environment in a living dog could change how well BNCT works.
This study is a proof of principle. BNCT works against canine HSA cells in the lab. But before it can reach the clinic, in vivo studies in dogs are needed to confirm real-world efficacy and safety.
